Experimental Hematology & Oncology (Sep 2021)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified

  • Kaiqi Liu,
  • Yan Li,
  • Shaowei Qiu,
  • Chunlin Zhou,
  • Shuning Wei,
  • Dong Lin,
  • Guangji Zhang,
  • Hui Wei,
  • Ying Wang,
  • Bingcheng Liu,
  • Xiaoyuan Gong,
  • Qiuyun Fang,
  • Yang Song,
  • Huijun Wang,
  • Chengwen Li,
  • Qinghua Li,
  • Lihua Wu,
  • Benfa Gong,
  • Yuntao Liu,
  • Jianxiang Wang,
  • Yingchang Mi

DOI
https://doi.org/10.1186/s40164-021-00239-w
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 3

Abstract

Read online

Abstract Acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our hospital, who were treated with venetoclax based treatment (venetoclax combining with azacitidine or chemotherapy). All 6 patients achieved CR. Five of the six patients received allo-HSCT, four patients were still alive in CR until the follow-up day. Our data provide preliminary evidence and show that venetoclax based regimens are effective and safety in patients with R/R ALAL-NOS.

Keywords